Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ: Alemtuzumab Long-term Follow-up in MS
NCT02255656Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2015
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 4 trial of alemtuzumab in multiple sclerosis (MS), sponsored by Sanofi. Started Jan 2015; status: completed.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02255656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02255656.